Influenza Vaccination Cuts Risk of Critical Illness in Children
During a season predominated by 2 vaccine-mismatched viruses, vaccination was estimated to reduce the risk of life-threatening influenza illness by 75%.
Influenza
Flu Vaccine May Not Protect Against Main Flu Strain
However, vaccine still likely to protect against severe illness and death
Concurrent Zoster, Flu Vaccines Tied to Lower Subsequent Flu Vaccine Uptake
Patients may misattribute adverse effects commonly caused by the zoster vaccine to the influenza vaccine
Flucelvax Quadrivalent Approval Expanded to Include Younger Patients
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
Prevnar 20 Coadministered With Flu Vaccine Immunogenic, Safe in Older Adults
The randomized, double-blind trial enrolled a total of 1796 participants, of which 1727 completed the study.
AAP Updates Influenza Vaccination Guidance for Children
Routine annual influenza vaccination is recommended for all patients 6 months of age and older who have no medical contraindications.
ACIP: Updated Vaccine Guidance for the 2021-2022 Influenza Season
Routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications.
Influenza Antiviral Treatments
FDA-approved antiviral therapies for the treatment and prophylaxis of influenza.
Antiviral Drugs for Influenza: Safety and Efficacy Outcomes Compared
The study authors obtained randomized clinical trials comparing oseltamivir, peramivir, zanamivir, and baloxavir with other active agents or placebo.
Flucelvax Quadrivalent Approval Expanded to Include Younger Patients
Flucelvax Quadrivalent is a subunit influenza vaccine manufactured using cell derived candidate vaccine viruses; it does not contain egg proteins or antibiotics.
